<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162756</url>
  </required_header>
  <id_info>
    <org_study_id>KT-US-472-0118</org_study_id>
    <nct_id>NCT04162756</nct_id>
  </id_info>
  <brief_title>Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies</brief_title>
  <acronym>ZUMA-18</acronym>
  <official_title>A Multicenter, Open-label, Expanded Access Study of KTE-X19 for the Treatment of Subjects With Relapsed/Refractory B-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to provide access to brexucabtagene autoleucel
      (KTE-X19) for individuals with relapsed or refractory (r/r) mantle cell lymphoma (MCL) until
      KTE-X19 is commercially available.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Relapse/Refractory Mantle Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Brexucabtagene Autoleucel (KTE-X19)</intervention_name>
    <description>A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Administered per package insert</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Administered per package insert</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Pathologically confirmed mantel cell lymphoma (MCL), with documentation of either
             overexpression of cyclin D1 or presence of t(11;14)

          -  Received at least one prior regimen for MCL. Prior therapy must have included:

               -  Anthracycline or bendamustine-containing chemotherapy, and

               -  Anti-CD20 monoclonal antibody therapy, and

               -  Treatment with Bruton's tyrosine kinase inhibitor (BTKi): ibrutinib,
                  acalabrutinib, or a BTKi in a clinical trial for r/r MCL.

          -  Relapsed or refractory disease, defined by the following:

               -  Disease progression after last regimen, or

               -  Failure to achieve a partial response (PR) or complete response (CR) to the last
                  regimen

          -  Magnetic resonance imaging (MRI) of the brain showing no evidence of central nervous
             system (CNS) lymphoma

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  Absolute neutrophil count (ANC) ≥ 1,000/uL

          -  Platelet count ≥ 75,000/uL

          -  Absolute lymphocyte count ≥ 100/uL

          -  Adequate renal, hepatic, pulmonary, and cardiac function defined as:

               -  Creatinine clearance (as estimated by Cockcroft Gault formula) ≥ 60 cc/min

               -  Serum alanine aminotransferase/aspartate aminotransferase (ALT)/AST) ≤ 2.5 x
                  upper limit of normal (ULN)

               -  Total bilirubin ≤ 1.5 mg/dl, except in individuals with Gilbert's syndrome

               -  Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion (except
                  trace or physiological) as determined by an echocardiogram (ECHO), and no
                  clinically significant electrocardiogram (ECG) findings

               -  No clinically significant pleural effusion

               -  Baseline oxygen saturation &gt; 92% on room air

        Key Exclusion Criteria:

          -  Presence or suspicion of fungal, bacterial, viral, or other infection that is
             uncontrolled or requiring intravenous (IV) antimicrobials for management.

          -  History of human immunodeficiency virus (HIV) infection or acute or chronic active
             hepatitis B or hepatitis C infection.

          -  Individuals with detectable cerebrospinal fluid (CSF) malignant cells or brain
             metastases or with a history of CNS lymphoma, CSF malignant cells, or brain metastases

          -  History or presence of CNS disorder, such as seizure disorder, cerebrovascular
             ischemia/hemorrhage, dementia, cerebellar disease, cerebral edema, posterior
             reversible encephalopathy syndrome, or any autoimmune disease with CNS involvement

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Kite Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>844-454-5483(1-844-454-KITE)</phone>
    <email>medinfo@kitepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>The University of TX MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

